Sonoma Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 03/31/25 | FY 03/31/24 | FY 03/31/23 | FY 03/31/22 | FY 03/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.3M | $12.7M | $13.3M | $12.6M | $18.6M |
| Cost of revenue | $8.8M | $8.0M | $8.8M | $8.6M | $12.1M |
| Gross profit | $5.5M | $4.7M | $4.5M | $4.0M | $6.6M |
| Selling, general & administrative | $7.4M | $7.6M | $8.8M | $9.8M | $9.5M |
| Research and development | $1.8M | $1.9M | $207,000 | $125,000 | $555,000 |
| Operating expenses | $9.2M | $9.4M | $9.0M | $9.9M | $10.0M |
| Operating income | -$3.7M | -$4.7M | -$4.6M | -$5.9M | -$3.4M |
| Interest expense | — | — | — | — | $12,000 |
| Pretax income | -$2.9M | -$5.0M | -$5.2M | -$5.4M | -$3.9M |
| Income tax expense | $550,000 | -$196,000 | -$33,000 | -$332,000 | $713,000 |
| Net income | -$3.5M | -$4.8M | -$5.2M | -$5.1M | -$4.0M |
| Balance Sheet | |||||
| Cash and equivalents | $5.4M | $3.1M | $3.8M | $7.4M | $4.2M |
| Current assets | $12.6M | $12.5M | $13.8M | $16.4M | $13.0M |
| Total assets | $13.7M | $14.7M | $16.2M | $18.8M | $15.0M |
| Current liabilities | $4.1M | $3.7M | $3.7M | $5.8M | $4.1M |
| Total liabilities | $9.3M | $8.6M | $8.3M | $10.1M | $9.6M |
| Stockholders' equity | $4.4M | $6.1M | $8.0M | $8.7M | $5.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$88,000 | -$2.4M | -$6.2M | -$4.2M | -$3.4M |
| Depreciation and amortization | $138,000 | $176,000 | $125,000 | $186,000 | $227,000 |
| Stock-based compensation | $224,000 | $516,000 | $669,000 | $382,000 | $371,000 |
| Capital expenditure | $80,000 | $2,000 | $269,000 | $137,000 | $179,000 |
| Free cash flow | -$168,000 | -$2.4M | -$6.4M | -$4.4M | -$3.6M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 1.7M · Free float 64.7%
Annual filing data through FY ended March 31, 2025; float as of July 4, 2026.